0001415889-23-013473.txt : 20230921 0001415889-23-013473.hdr.sgml : 20230921 20230921165034 ACCESSION NUMBER: 0001415889-23-013473 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230921 FILED AS OF DATE: 20230921 DATE AS OF CHANGE: 20230921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ferguson Matthew CENTRAL INDEX KEY: 0001304079 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39577 FILM NUMBER: 231269582 MAIL ADDRESS: STREET 1: C/O FOXHOLLOW TECHNOLOGIES, INC. STREET 2: 740 BAY ROAD CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ELUTIA INC. CENTRAL INDEX KEY: 0001708527 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474790334 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12510 PROSPERITY DRIVE STREET 2: SUITE 370 CITY: SILVER SPRING STATE: MD ZIP: 20904 BUSINESS PHONE: 240-247-1143 MAIL ADDRESS: STREET 1: 12510 PROSPERITY DRIVE STREET 2: SUITE 370 CITY: SILVER SPRING STATE: MD ZIP: 20904 FORMER COMPANY: FORMER CONFORMED NAME: AZIYO BIOLOGICS, INC. DATE OF NAME CHANGE: 20170605 4 1 form4-09212023_080929.xml X0508 4 2023-09-21 0001708527 ELUTIA INC. ELUT 0001304079 Ferguson Matthew C/O ELUTIA INC. 12510 PROSPERITY DRIVE, SUITE 370 SILVER SPRING MD 20904 false true false false CHIEF FINANCIAL OFFICER 0 Class A Common Stock 2023-09-21 4 A 0 70053 A 120519 D Warrants (rights to buy) 1.4275 2023-09-21 4 A 0 105080 A 2023-09-21 Class A Common Stock 105080 105080 D The reported securities are included within the 70,053 Units purchased by the reporting person for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock and one warrant to purchase one and one-half shares of Class A Common Stock. Includes 901 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan. The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028. /s/ Jeffrey Hamet, Attorney-in-Fact for Matthew Ferguson 2023-09-21